Daratumumab for antibody-mediated rejection : Is it time to target the real culprit?
Copyright © 2023 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved..
We report the case of a sensitized woman who underwent successful transplantation after a desensitization protocol, with an optically normal 8-day biopsy. At 3 months, she developed active antibody-mediated rejection (AMR) due to preformed donor-specific antibodies. It was decided to treat the patient with daratumumab, an anti-CD38 monoclonal antibody. The mean fluorescence intensity of donor-specific antibodies decreased, pathologic signs of AMR regressed, and kidney function returned to normal. A molecular assessment of biopsies was retrospectively performed. By doing so, regression of the molecular signature of AMR was evidenced between the second and third biopsies. Interestingly, the first biopsy revealed a gene expression profile of AMR, which helped retrospectively classify this biopsy as AMR, illustrating the relevance of molecular phenotyping of biopsy in high-risk situations such as desensitization.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons - 23(2023), 12 vom: 01. Dez., Seite 1990-1994 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
de Nattes, Tristan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4Z63YK6E0E |
|---|
| Anmerkungen: |
Date Completed 04.12.2023 Date Revised 04.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ajt.2023.06.018 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359153623 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359153623 | ||
| 003 | DE-627 | ||
| 005 | 20231226080253.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ajt.2023.06.018 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1197.xml |
| 035 | |a (DE-627)NLM359153623 | ||
| 035 | |a (NLM)37414251 | ||
| 035 | |a (PII)S1600-6135(23)00549-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a de Nattes, Tristan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Daratumumab for antibody-mediated rejection |b Is it time to target the real culprit? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2023 | ||
| 500 | |a Date Revised 04.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a We report the case of a sensitized woman who underwent successful transplantation after a desensitization protocol, with an optically normal 8-day biopsy. At 3 months, she developed active antibody-mediated rejection (AMR) due to preformed donor-specific antibodies. It was decided to treat the patient with daratumumab, an anti-CD38 monoclonal antibody. The mean fluorescence intensity of donor-specific antibodies decreased, pathologic signs of AMR regressed, and kidney function returned to normal. A molecular assessment of biopsies was retrospectively performed. By doing so, regression of the molecular signature of AMR was evidenced between the second and third biopsies. Interestingly, the first biopsy revealed a gene expression profile of AMR, which helped retrospectively classify this biopsy as AMR, illustrating the relevance of molecular phenotyping of biopsy in high-risk situations such as desensitization | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a antibody-mediated rejection | |
| 650 | 4 | |a antibody-secreting cells | |
| 650 | 4 | |a daratumumab | |
| 650 | 4 | |a immunosuppressive therapy | |
| 650 | 4 | |a kidney transplantation | |
| 650 | 4 | |a molecular diagnosis | |
| 650 | 7 | |a daratumumab |2 NLM | |
| 650 | 7 | |a 4Z63YK6E0E |2 NLM | |
| 650 | 7 | |a Isoantibodies |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 700 | 1 | |a Kaveri, Rangolie |e verfasserin |4 aut | |
| 700 | 1 | |a Farce, Fabienne |e verfasserin |4 aut | |
| 700 | 1 | |a François, Arnaud |e verfasserin |4 aut | |
| 700 | 1 | |a Guerrot, Dominique |e verfasserin |4 aut | |
| 700 | 1 | |a Hanoy, Mélanie |e verfasserin |4 aut | |
| 700 | 1 | |a Laurent, Charlotte |e verfasserin |4 aut | |
| 700 | 1 | |a Candon, Sophie |e verfasserin |4 aut | |
| 700 | 1 | |a Bertrand, Dominique |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons |d 2001 |g 23(2023), 12 vom: 01. Dez., Seite 1990-1994 |w (DE-627)NLM119667924 |x 1600-6143 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:12 |g day:01 |g month:12 |g pages:1990-1994 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ajt.2023.06.018 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 12 |b 01 |c 12 |h 1990-1994 | ||